In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Analysts working with top YouTube channels report Shorts older than 30 days receive fewer views. YouTube hasn't confirmed any algorithm change. Retention analysts say Shorts older than 28-30 days are ...
Instagram said it is "leading the way" in offering such transparency and control (Representational) Instagram on Wednesday unveiled a new AI-powered feature that lets users view and adjust the ...
Instagram is introducing a new tool that lets you see and control your algorithm, starting with Reels, the company announced on Wednesday. The new tool, called “Your Algorithm,” lets you view the ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback